Abstract-In 2018, the American Heart Association published a Scientific Statement on resistant hypertension. We compared the prevalence of apparent treatment-resistant hypertension (aTRH) among US adults as defined in the 2018 and 2008 American Heart Association Scientific Statements using data from 4158 participants with hypertension, taking antihypertensive medication in the 2009 to 2014 National Health and Nutrition Examination Survey. Blood pressure (BP) was measured 3 times, and antihypertensive medication classes were identified through a pill bottle review. 
R esistant hypertension is defined as having a blood pressure (BP) that remains above the recommended goal, despite treatment with 3 classes of antihypertensive medication or treatment with ≥4 classes of antihypertensive medication with any level of BP. 1, 2 In 2018, the American Heart Association (AHA) published an update to its 2008 Scientific Statement on resistant hypertension. The major difference in the definitions of resistant hypertension between these Scientific Statements is the BP goal. The 2008 AHA Scientific Statement defined BP control as systolic BP (SBP) <140 mm Hg and diastolic BP (DBP) <90 mm Hg for most adults, with SBP <130 mm Hg and DBP <80 mm Hg for adults with diabetes mellitus or chronic kidney disease (CKD). 1 The 2018 AHA Scientific Statement on resistant hypertension was consistent with the 2017 American College of Cardiology (ACC)/AHA BP clinical practice guideline, in defining BP control as SBP <130 mm Hg and DBP <80 mm Hg for all adults <65 years of age and for adults ≥65 years of age with diabetes mellitus, CKD, history of cardiovascular disease (CVD), or 10-year predicted atherosclerotic CVD (ASCVD) risk ≥10% on the pooled cohort risk equations. 2, 3 Only SBP <130 mm Hg was used to define BP control for adults ≥ 65 years of age without diabetes mellitus, CKD, history of CVD or 10-year predicted ASCVD risk ≥ 10%. In the 2017 ACC/AHA BP guideline, it was estimated that the prevalence of apparent treatment-resistant hypertension (aTRH) would be 4% higher when SBP <130 mm Hg and DBP <80 mm Hg was used to define control, but the guideline writing committee noted that this estimate needed to be validated in future studies. 3 The term aTRH is used for population-based studies in which it is not possible to exclude pseudoresistance (eg, inaccurate measurement of BP, medication nonadherence, or white coat effect).
The primary purpose of the present study was to compare the prevalence and characteristics of adults with aTRH using the definitions in the 2018 versus the 2008 AHA Scientific Statement. A secondary goal was to determine the most frequent antihypertensive medication combinations and the corresponding BP control rates for US adults taking ≥3 classes of antihypertensive medication. Also, we examined the use of thiazide-like diuretics and mineralocorticoid receptor blockers among US adults with aTRH according to the 2018 AHA Scientific Statement. To accomplish these goals, we analyzed data from the 2009 to 2014 US National Health and Nutrition Examination Survey (NHANES).
Methods
Data used in the current study are available on the National Center for Health Statistics of the Center for Disease Control and Prevention website: https://wwwn.cdc.gov/nchs/nhanes/Default.aspx. Other study material is available from the corresponding author. The NHANES is a cross-sectional survey of the US population designed and conducted by National Center for Health Statistics of the Center for Disease Control and Prevention. 4 Since 1999 to 2000, NHANES has been conducted in 2-year cycles. For each 2-year cycle, a stratified, multistage, probability sampling method was used to identify a noninstitutionalized US population for enrollment. The current analysis included data from the 2009 to 2010, 2011 to 2012, and 2013 to 2014 cycles, pooled together. The analysis was restricted to participants ≥20 years of age who self-reported taking antihypertensive medication and had at least 1 class of antihypertensive medication identified during a pill bottle review conducted as part of the NHANES examination (n=4520). We excluded 362 participants without 3 BP measurements obtained during their study exam resulting in a final sample size of 4158 participants for all analyses. 
Data Collection
NHANES data were collected through questionnaires and a medical examination conducted at a mobile clinic. Using questionnaires, data on age, race/ethnicity, sex, a previous diagnosis of diabetes mellitus, coronary heart disease, myocardial infarction, stroke, and heart failure were collected. Self-reported use of antihypertensive and glucose-lowering medication was also assessed.
BP Measurement and Antihypertensive Medication Use
Trained physicians measured BP 3 times using a mercury sphygmomanometer and an appropriately sized BP cuff. The first measurement was performed after participants had rested, seated for 5 minutes with a 30-second interval between readings. The average of the 3 BP measurements was used to define SBP and DBP. Quality control procedures included recertification of all physicians every 3 months and retraining every 12 months. There was no digit preference for either SBP or DBP (Table S1 in the online-only Data Supplement).
Antihypertensive Medication Classes and aTRH
Participants were asked to bring all prescription medications taken in the prior 2 weeks to their NHANES medical evaluation. Pill bottles were reviewed, and medication names were recorded and coded into drug classes based on their generic equivalents. These classes included angiotensin-converting enzyme (ACE) inhibitors, α-blockers, angiotensin receptor blockers, β-blockers, dihydropyridine and nondihydropyridine calcium channel blockers (CCBs), central acting α2-agonists, mineralocorticoid receptor antagonists, thiazide or thiazide-like diuretics, potassium-sparing diuretics, loop diuretics, and vasodilators. Single-pill combinations were categorized into their component classes. aTRH was defined using the BP goals for adults taking antihypertensive medication in the 2008 and 2018 AHA Scientific Statements as described previously and presented in Table 1 .
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Covariates
Diabetes mellitus was defined as a fasting serum glucose ≥126 mg/ dL, nonfasting serum glucose ≥200 mg/dL, hemoglobin A1c ≥6.5%, or self-report of a history of diabetes mellitus with concurrent glucose-lowering medication use. Estimated glomerular filtration rate (eGFR) was calculated using serum creatinine levels and the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. 5 An albumin-to-creatinine ratio (ACR) was calculated using spot urine samples. CKD was defined as an eGFR <60 mL/min per 1.73 m 2 or ACR >30 mg/g. History of CVD was defined by self-reported prior diagnosis of myocardial infarction, coronary heart disease, stroke, or heart failure. The pooled cohort risk equations were used to calculate 10-year predicted risk for ASCVD among participants without a history of CVD. 6 Participants were categorized into 5 mutually exclusive groups, including history of CVD and no history of CVD with 10-year predicted ASCVD risk <5%, 5% to <10%, 10% to <20%, and ≥20%.
Statistical Analysis
The distribution of US adults by number of antihypertensive medication classes being taken cross-classified by SBP/DBP categories (<120/80, 120-129/<80, 130-139/80-89, and ≥140/90 mm Hg) was calculated. Additionally, we calculated the proportion of US adults taking antihypertensive medication with uncontrolled BP, defined using the 2008 and 2018 Scientific Statements separately, overall and by number of classes being taken. Characteristics of US adults taking antihypertensive medication were computed for 3 mutually exclusive groups defined by not having aTRH using AHA indicates American Heart Association; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; and SBP, systolic blood pressure.
*Except for adults ≥65 y of age without diabetes mellitus, CKD, history of CVD, or 10-y predicted risk ≥10% on the pooled cohort risk equations. Only SBP is used for adults ≥65 y of age without diabetes mellitus, CKD, history of CVD, or 10-y predicted risk ≥10% on the pooled cohort risk equations. Table S2 . In a secondary analysis, we calculated the prevalence of aTRH using a modification of the 2008 and 2018 definitions in which use of a thiazide diuretic was required to be considered as having aTRH. Among US adults taking ≥3 classes of antihypertensive medication, we calculated the frequency for which the most common 3 antihypertensive medication combinations were being taken. Additionally, the percentage of US adults taking these medication combinations with an SBP <140 mm Hg and DBP <90 mm Hg and with an SBP <130 mm Hg and DBP <80 mm Hg, separately, were computed. In a final analysis, we calculated the proportion of US adults with aTRH using the definition in the 2018 Scientific Statement taking either chlorthalidone or indapamide and spironolactone or eplerenone.
The multistage sampling approach used in NHANES was taken into account and the calculations were weighted to obtain nationally representative estimates. These weights were recalibrated based on the proportion of participants missing data by age, sex, and race-ethnicity within each NHANES cycle, assuming that data within strata were missing at random. Data management was conducted using SAS, version 9.4 (SAS Institute, Cary, NC), and data analysis was conducted using Stata V15 (Stata Corporation, College Station, TX).
Results
Overall, 36.7%, 36.1%, 17.6%, and 9.7% of US adults taking antihypertensive medication were taking 1, 2, 3, or ≥4 classes of antihypertensive medication, respectively ( Figure 1 ). Among US adults taking antihypertensive medication, 4.3% and 5.7% were taking 3 classes of antihypertensive medication and had SBP between 130 and 139 mm Hg or DBP between 80 and 89 mm Hg and SBP ≥140 mm Hg or DBP ≥90 mm Hg, respectively. Also, 2.2% and 2.8% were taking ≥4 classes of antihypertensive medication and had SBP between 130 and 139 mm Hg or DBP between 80 and 89 mm Hg and SBP ≥140 mm Hg or DBP ≥90 mm Hg, respectively. The proportion of US adults taking antihypertensive medication with uncontrolled BP, overall and by number of drug classes being taken, is presented in Table S3 .
Adults with aTRH according to both the 2008 and 2018 definitions of BP control were older, more likely to be nonHispanic black, and more likely to have diabetes mellitus, CKD, ACR >30 mg/g, eGFR <60 mL/min per 1.73 m 2 , a 10-year predicted ASCVD risk ≥20%, or a history of CVD compared with their counterparts without aTRH ( When requiring the use of a thiazide or thiazide-like diuretic to be considered as having aTRH, the prevalence of aTRH was 10.3% according to the 2008 definition and 11.4% using the 2018 definition (Table S5) . In this latter analysis, the difference in the prevalence of aTRH between the 2008 and 2018 Scientific Statements was 1.1% (95% CI, 0.8%-1.5%).
Among US adults taking ≥3 classes of antihypertensive medication, the most common 3-drug combinations included an (1) ACE inhibitor, β-blocker, and thiazide diuretic; (2) ACE inhibitor, dihydropyridine CCB, and β-blocker; or (3) angiotensin receptor blocker, β-blocker, and thiazide diuretic ( Table 4 ). The proportion with SBP/DBP <140/90 mm Hg ranged from 54.4% among those taking an angiotensin receptor blocker, dihydropyridine CCB, and β-blocker to 76.0% among their counterparts taking an ACE inhibitor, dihydropyridine CCB, and thiazide diuretic. The proportion with SBP/ DBP <130/80 mm Hg was <50% in each of the subgroups except for those taking an ACE inhibitor, β-blocker, and loop diuretic, where it was 54.6%.
Overall, 3.2% of US adults with aTRH according to the 2018 Scientific Statement were taking recommended long-acting thiazide-like diuretics (chlorthalidone or indapamide), and 9.0% were taking mineralocorticoid receptor blockers (spironolactone or eplerenone; Figure 2 ). Whereas the proportion of US adults with aTRH taking a thiazide-like diuretic was similar for those with uncontrolled and controlled BP (2.8% and 4.4%), the proportion taking a mineralocorticoid receptor blocker was lower among those with uncontrolled versus controlled BP (4.7% versus 22.8%). In a secondary analysis, in which we required adults to be taking a thiazide or thiazide-like diuretic to be considered as having aTRH, the prevalence of aTRH was 10.3% using the 2008 definition and 11.4% using the 2018 definition. Overall, using the 2018 Scientific Statement definition instead of the 2008 Scientific Statement definition for resistant hypertension increased the prevalence of aTRH among US adults by only 1.1% to 2.0%. This marginal change in the prevalence of aTRH was the result of lower BP control thresholds used to define aTRH by AHA in 2018 compared with 2008.
Discussion
The current estimates are consistent with previous population-based studies in which the prevalence of aTRH among adults with hypertension has been reported as ≈12% to 15%. 2 The prevalence of aTRH was higher in the current study when compared with a previous analysis of US adults taking antihypertensive medication in NHANES 2003 to 2008 (12.8%). 7 This is possibly because of the fact that the latter study defined BP control as <140/90 mm Hg for all adults, whereas we used the same definition for the general population but BP <130/80 mm Hg for adults with diabetes mellitus or CKD. 7 The prevalence of aTRH among those with diabetes mellitus and CKD was the same when using the 2008 and 2018 definitions.
The term aTRH is used when at least 1 of the following elements of information is missing: medication doses, assessment of medication adherence, or out-of-office BP measurements by home BP monitoring or ambulatory BP monitoring. None of this information was available in the current study. Therefore, we cannot be certain that medications were being taken at maximal or maximally tolerated doses and on a regular basis in accordance with caregiver instructions. In addition, it is impossible to determine whether the white coat effect or office BP above goal but out-of-office BP below goal might have influenced the prevalence of resistant hypertension reported here. It has been established that a substantial proportion of adults taking ≥3 classes of antihypertensive medication have ≥1 of these factors. 8, 9 For this reason, both the 2018 AHA Scientific Statement and the 2018 European Society of Because of rounding, the numbers in the column 2018 but Not 2008 do not always equal the estimate in the 2018 Scientific Statement minus 2008 Scientific Statement columns. ACR indicates albumin-to-creatinine ratio; AHA, American Heart Association; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; and SBP, systolic blood pressure.
*There is no CI because, by definition, no participants with SBP/DBP <130/80 or with ≥140/90 mm Hg have apparent treatmentresistant hypertension by one scientific statement but not the other.
†All participants with a history of CVD are in this category regardless of their 10-y predicted risk.
Cardiology/European Society of Hypertension hypertension guidelines now require exclusion of medication nonadherence and white coat effect to make the diagnosis of resistant hypertension. 2, 10 Therefore, the prevalence of resistant hypertension may be lower than the estimates from the current study. In contrast, we cannot exclude the possibility that some US adults with uncontrolled BP on 1 or 2 classes of antihypertensive medication might still have uncontrolled BP if they had been taking ≥3 classes of antihypertensive medications.
The characteristics of US adults with aTRH according to the 2008 and the 2018 AHA Scientific Statement definitions are consistent with prior studies. 7, [11] [12] [13] Individuals with aTRH are more likely to have CVD risk factors, including diabetes mellitus, CKD, and a high 10-year predicted ASCVD risk. In the current study, US adults with aTRH according to the 2018 but not the 2008 Scientific Statement on resistant hypertension had a 10-year predicted ASCVD risk similar to those without aTRH according to either Scientific Statement. The implication of this finding is not clear, but its impact may be small because most people with aTRH according to the 2018 Scientific Statement definition also had aTRH according to the 2008 Scientific Statement.
We analyzed the combinations of antihypertensive medications among US adults taking ≥3 drug classes. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended a diuretic as first-step drug therapy with agents from other major drug classes (including β-blockers) to be added in a stepped care therapy approach.
14 Consequently, β-blockers were included among the drug classes recommended by the 2008 Scientific Statement. 1 The 2017 ACC/AHA and the 2018 European Society of Cardiology/European Society of Hypertension clinical practice guidelines recommend combination therapy from 4 drug classes (diuretics, CCBs, ACE inhibitors, and angiotensin receptor blockers) but allow for β-blockers as second-line agents 3, 10 or when a compelling indication exists for their use in managing a comorbidity. In the 2018 Scientific Statement, β-blockers are recommended in the management of resistant hypertension as a fifth add-on drug under specific clinical circumstances. 2 In the current analysis, β-blockers were used as a component of the most frequently used 3-drug regimens among US adults. However, this is likely to change as guideline recommendations are incorporated into clinical practice over time.
The frequency with which the drug combinations were used among US adults did not correlate with the degree of BP control to <140/90 or <130/80 mm Hg. As expected, fewer individuals achieved BP control <130/80 mm Hg compared with <140/90 mm Hg. Prospective assessment of BP control rates comparing different combinations of antihypertensive agents in resistant hypertension is not currently available and would be helpful to facilitate evidence-based therapeutic decision-making in the future.
Both the 2017 ACC/AHA and the 2018 European Society of Cardiology/European Society of Hypertension hypertension guidelines recommend initiation of antihypertensive drug therapy with 2 drugs in combination for most adults with hypertension. 3, 10 According to the current study, more than onethird of US adults taking antihypertensive medication were taking a single drug class and in more than half of these individuals, BP was uncontrolled by the 2017 ACC/AHA guideline criteria. A total of 17.6% of adults taking antihypertensive drugs were taking 3 antihypertensive medication classes with only 7.6% having their BP controlled to <130/80 mm Hg.
Diuretic administration is critically important in resistant hypertension because the majority of patients have extracellular fluid volume expansion. 2, 15, 16 Thiazide-like diuretics (ie, chlorthalidone and indapamide) have a substantial evidence base for BP control and reduction in CVD events in resistant hypertension. [17] [18] [19] [20] According to the 2018 AHA Scientific Statement, the first step in the management of resistant hypertension is to substitute a thiazide-like diuretic for a thiazide diuretic to achieve BP control. 2 In the present study, we documented infrequent use of thiazide-like diuretics among US adults with aTRH. Similarly, there was little use of mineralocorticoid receptor antagonists (spironolactone or eplerenone) in US adults with aTRH. Because prior studies strongly support the efficacy of mineralocorticoid receptor blockers to reduce BP in resistant hypertension, the 2018 AHA Scientific Statement recommended these agents as the primary (fourth) add-on drug in the management of resistant hypertension.
2,21-25 Adults with resistant hypertension have an 2 In view of the documented poor prognosis in uncontrolled resistant hypertension, increased attention to substitution of a thiazide-like diuretic and addition of a mineralocorticoid receptor blocker should be of major critical importance in the management of resistant hypertension.
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The current study has several strengths. NHANES provides nationally representative estimates for the noninstitutionalized US population, and the results of this analysis have broad generalizability. NHANES enrolled a large sample size and oversampled population groups that facilitated the conduct of subgroup analysis. BP was measured following a standardized protocol. The classes of antihypertensive medication being taken were verified by a pill bottle review. However, the results of this study should be interpreted in the context of known and potential limitations. The data we present applied the 2018 definition of aTRH and BP control to data collected before the publication of these recommendations. Data were not collected on medication dose and frequency and medication adherence. Additionally, out-of-office BP monitoring was not performed. Therefore, some participants were likely misclassified as having resistant hypertension when they in fact had pseudoresistant hypertension. This may have led to overestimation of the prevalence of resistant hypertension. Also, BP was measured at a single visit in NHANES. The 2017 ACC/AHA hypertension guideline recommends basing the diagnosis of hypertension on the average of multiple BP measurements obtained at ≥2 visits. Also, the NHANES BP measurement protocol included the use of a mercury sphygmomanometer, which likely differs from the usual approach in most settings. However, high agreement for SBP and DBP levels was present in a study comparing the BP measurement methods in NHANES to a protocol using automated office BP measurements. 26 
Perspectives
In conclusion, analysis of 2009 to 2014 NHANES data demonstrates the prevalence of aTRH of 19.7% when defined according to the 2018 AHA Scientific Statement definition. Compared with prior recommendations, using the most recently recommended SBP/DBP cut-points for defining uncontrolled BP resulted in only a modest increase in the prevalence of aTRH. However, the vast majority of US adults with aTRH were not taking thiazide-like diuretics and mineralocorticoid receptor blockers as recommended by the 2018 Scientific Statement. Increasing the use of thiazide-like diuretics and mineralocorticoid receptor blockers has the potential to substantially improve BP control and reduce the prevalence of resistant hypertension in the future. Heart Association Scientific Statement on resistant hypertension, uncontrolled blood pressure (BP) was defined as systolic BP ≥130 mm Hg and diastolic BP ≥80 mm Hg. For adults ≥65 y of age without diabetes mellitus, chronic kidney disease, history of cardiovascular disease, or 10-y predicted risk ≥10% on the pooled cohort risk equations, only systolic BP ≥130 mm Hg is used to define uncontrolled BP. According to the 2018 American Heart Association Scientific Statement on resistant hypertension, controlled BP was defined as systolic BP <130 mm Hg and diastolic BP <80 mm Hg. For adults ≥65 y of age without diabetes mellitus, chronic kidney disease, history of cardiovascular disease, or 10-y predicted risk ≥10% on the pooled cohort risk equations, controlled BP was defined as systolic BP <130 mm Hg.
